Matica Bio, KaliVir Collaborate on Scalable Cancer Immunotherapy Production
Matica Bio, KaliVir partner to scale cancer immunotherapy development using advanced viral vector technology.
Matica Biotechnology and KaliVir Immunotherapeutics have teamed up to drive new immunotherapy solutions for cancer treatment. Through this partnership, KaliVir will leverage Matica Bio’s MatiMax™ cell line to produce viral vectors optimized for delivering therapeutic genes, potentially enhancing the efficiency of these cancer-fighting therapies.
With this collaboration, KaliVir’s oncolytic viruses will progress more efficiently through development stages, thanks to Matica’s state-of-the-art Texas facilities designed for scalable manufacturing.
Together, they aim to expand access to innovative treatments by producing next-generation therapies for broader clinical applications.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
IDEAYA Biosciences Achieves 17.4-Month Median OS with IDE849 ADC in Relapsed SCLC
FDA Issues Twelve Biologics Guidance Documents Covering Container Closure, Blood Manufacturing, and Biosimilars
Discussion